Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
dc.contributor.author | Fontana, Robert J. | en_US |
dc.contributor.author | Hughes, Eric A. | en_US |
dc.contributor.author | Appelman, Henry | en_US |
dc.contributor.author | Hindes, Robert | en_US |
dc.contributor.author | Dimitrova, Dessislava | en_US |
dc.contributor.author | Bifano, Marc | en_US |
dc.date.accessioned | 2012-09-05T14:46:00Z | |
dc.date.available | 2013-10-18T17:47:29Z | en_US |
dc.date.issued | 2012-09 | en_US |
dc.identifier.citation | Fontana, Robert J.; Hughes, Eric A.; Appelman, Henry; Hindes, Robert; Dimitrova, Dessislava; Bifano, Marc (2012). "Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation ." Liver Transplantation 18(9): 1053-1059. <http://hdl.handle.net/2027.42/93517> | en_US |
dc.identifier.issn | 1527-6465 | en_US |
dc.identifier.issn | 1527-6473 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/93517 | |
dc.description.abstract | A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally administered nonstructural 5A replication complex inhibitor, in combination with peginterferon α (PEG‐IFNα) and ribavirin in an LT recipient. A 49‐year‐old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8.4 mg/dL. Despite partial virological suppression with PEG‐IFNα and ribavirin, progressive allograft failure ensued and culminated in retransplantation at 9 months. Three months after the second transplant, DCV (20 mg/day), PEG‐IFNα2a (180 μg/week), and ribavirin (800 mg/day) were prescribed for early recurrent cholestatic HCV. Serum HCV RNA became undetectable at week 3 of treatment and remained undetectable during 24 weeks of triple therapy and during the posttreatment follow‐up. DCV was well tolerated, and the trough drug levels were within the targeted range throughout the treatment. The cyclosporine trough levels were also stable during and after therapy. In conclusion, the lack of anticipated drug‐drug interactions between DCV and calcineurin inhibitors and the potent antiviral efficacy of DCV make this agent (in combination with PEG‐IFN and ribavirin) an attractive antiviral regimen worthy of further study in LT recipients with recurrent HCV. Liver Transpl, 2012. © 2012 AASLD. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Pathology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109‐0362 | en_US |
dc.contributor.affiliationother | Bristol‐Myers Squibb, Princeton, NJ | en_US |
dc.contributor.affiliationother | Gilead Sciences, Foster City, CA | en_US |
dc.identifier.pmid | 22706796 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/93517/1/23482_ftp.pdf | |
dc.identifier.doi | 10.1002/lt.23482 | en_US |
dc.identifier.source | Liver Transplantation | en_US |
dc.identifier.citedreference | Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971 ‐ 976. | en_US |
dc.identifier.citedreference | Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569 ‐ 4574. | en_US |
dc.identifier.citedreference | Fridell RA, Wang C, Sun JH, O'Boyle DR II, Nower P, Valera L, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924 ‐ 1935. | en_US |
dc.identifier.citedreference | Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956 ‐ 1965. | en_US |
dc.identifier.citedreference | Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b‐infected null responders. Hepatology 2012; 55: 742 ‐ 748. | en_US |
dc.identifier.citedreference | Suzuki F, Chayama K, Kawakami Y, Toyota J, Karinon Y, Mochida S, et al. Daclatasvir (DCV: BMS‐790052), an NS5A replication complex inhibitor, in combination with peginterferon alfa‐2b and ribavirin in Japanese treatment naïve and non‐responder patients with chronic HCV genotype 1 infection [abstract]. Hepatology 2011; 54 ( suppl 1 ): LB22. | en_US |
dc.identifier.citedreference | Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216 ‐ 224. | en_US |
dc.identifier.citedreference | Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez‐Torres M, Shafran S, et al. Daclatasvir (DCV; BMS‐790052), an NS5A replication complex inhibitor, combined with peginterferon‐alfa‐2a and ribavirin in treatment‐naive HCV‐genotype 1 or 4 subjects: phase COMMAND‐1 study interim week 24 results [abstract]. Hepatology 2011; 54:( suppl 1 ): A227. | en_US |
dc.identifier.citedreference | Bifano M, Sevinsky H, Persson A, Hwang C, Kandoussi H, Jian H, et al. Daclatasvir (DCV; BMS‐790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract]. Hepatology 2011; 54:( suppl 1 ): A1340. | en_US |
dc.identifier.citedreference | Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30 ‐ 34. | en_US |
dc.identifier.citedreference | Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84 ‐ 92. | en_US |
dc.identifier.citedreference | Narang TK, Ahrens W, Russo MW. Post‐liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228 ‐ 1235. | en_US |
dc.identifier.citedreference | Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus‐related graft cirrhosis. Liver Transpl 2003; 9: 228 ‐ 235. | en_US |
dc.identifier.citedreference | Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434 ‐ 440. | en_US |
dc.identifier.citedreference | Alcaide ML, Abbo L, Pano JR, Gaynor JJ, Tryphonopoulos P, Weppler D, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant 2008; 22: 502 ‐ 507. | en_US |
dc.identifier.citedreference | Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case‐control study. Liver Transpl 2005; 11: 320 ‐ 325. | en_US |
dc.identifier.citedreference | Naoum C, Perissios A, Varnavas V, Lagos D. Treatment of herpes zoster with interferon alpha‐2A. Int J Dermatol 1996; 35: 749 ‐ 750. | en_US |
dc.identifier.citedreference | Selzner N, Guindi M, Renner EL, Berenguer M. Immune‐mediated complications of the graft in interferon‐treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207 ‐ 217. | en_US |
dc.identifier.citedreference | Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune‐mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132 ‐ 1139. | en_US |
dc.identifier.citedreference | Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus‐specific T‐cell mediated immunity after liver transplantation. Hepatology 2005; 41: 72 ‐ 81. | en_US |
dc.identifier.citedreference | Sharma P, Jafri M, Appelman H, McKenna B, Sullivan P, Fontana RJ, Lok ASF. Immunological dysfunction on antiviral therapy for hepatitis C recurrence after liver transplantation is associated with poor graft survival [abstract]. Am J Transplant 2011; 11: A828. | en_US |
dc.identifier.citedreference | Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159 ‐ 1165. | en_US |
dc.identifier.citedreference | Sulkowski MJ, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, et al. Potent viral suppression with all‐oral combination of daclatasvir (NS5A inhibitor) and GS‐7977 (NS5B inhibitor), +/− ribavirin, in treatment naïve patients with chronic HCV genotype 1, 2, and 3 [abstract]. J Hepatol 2012; 56. | en_US |
dc.identifier.citedreference | Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS‐790052) and NS3 protease inhibitor asunaprevir (BMS‐650032) in HCV genotype 1 infected null responders or patients ineligible/intolerant to peginterferon/ribavirin [abstract]. J Hepatol 2012; 56. | en_US |
dc.identifier.citedreference | Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405 ‐ 2416. | en_US |
dc.identifier.citedreference | Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT‐2 Investigators. N Engl J Med 2011; 364: 1195 ‐ 1206. | en_US |
dc.identifier.citedreference | Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND‐2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207 ‐ 1217. | en_US |
dc.identifier.citedreference | Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20 ‐ 27. | en_US |
dc.identifier.citedreference | Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919 ‐ 940. | en_US |
dc.identifier.citedreference | Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167 ‐ 177. | en_US |
dc.identifier.citedreference | Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250 ‐ 256. | en_US |
dc.identifier.citedreference | Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long‐term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815 ‐ 820. | en_US |
dc.identifier.citedreference | Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV‐related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673 ‐ 684. | en_US |
dc.identifier.citedreference | Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889 ‐ 896. | en_US |
dc.identifier.citedreference | Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, et al.; for Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH‐C). Hepatitis C virus‐infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54: 418 ‐ 424. | en_US |
dc.identifier.citedreference | Guillouche P, Féray C. Systematic review: anti‐viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163 ‐ 174. | en_US |
dc.identifier.citedreference | Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100 ‐ 1108. | en_US |
dc.identifier.citedreference | Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on‐treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53 ‐ 58. | en_US |
dc.identifier.citedreference | Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426 ‐ 2433. | en_US |
dc.identifier.citedreference | Carrión JA, Navasa M, García‐Retortillo M, García‐Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746 ‐ 1756. | en_US |
dc.identifier.citedreference | Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459 ‐ 465. | en_US |
dc.identifier.citedreference | Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417 ‐ 2428. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.